

Listing of Claims:

This listing of claims will replace all prior versions and listings of the claims in the present application.

Claims 1-3. (Canceled)

4. (Previously presented) A method of treating a patient suffering from diabetic cardiomyopathy, comprising administering an effective amount of a compound selected from the group consisting of Glucagon-Like Peptide-1 (GLP-1), GLP-1 analogs, and GLP-1-like peptides, to a patient suffering from diabetic cardiomyopathy.

5. (Previously presented) The method of claim 4, wherein the administration is continuous.

6. (Previously presented) The method of claim 4, wherein the administration is parenteral.

7. (Previously presented) The method of claim 4, wherein said effective amount of said compound is effective to cause a reduction in the plasma or heart norepinephrine level.

Claims 8-9. (Canceled)

10. (Previously presented) The method of claim 6, wherein said compound is administered in a dose of from about 0.1-10 pmol/kg/min.

11. (Previously presented) The method of claim 4 wherein said compound is administered subcutaneously in a dose of about 0.5-50 pmol/kg/min.

12. (Previously presented) The method of claim 4 wherein said compound is administered in a dose of up to 10.0 nmol/kg.

Claim 13. (Canceled)

14. (Previously presented) The method of claim 4 wherein said compound is administered intravenously in a dose of about 0.1-10 pmol/kg/min.

Claims 15-16. (Canceled)

17. (Previously presented) The method of claim 4, wherein said compound is selected from the group consisting of GLP-1(1-37), GLP-1(1-36)NH₂, GLP-1(7-37), and GLP-1(7-36)NH₂.

Claims 18-40. (Canceled)